Recommendations for diagnosing STIC: a systematic review and meta-analysis.


Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 16 08 2021
accepted: 22 11 2021
revised: 27 10 2021
pubmed: 2 12 2021
medline: 26 4 2022
entrez: 1 12 2021
Statut: ppublish

Résumé

Our understanding of the oncogenesis of high-grade serous cancer of the ovary and its precursor lesions, such as serous tubal intraepithelial carcinoma (STIC), has significantly increased over the last decades. Adequate and reproducible diagnosis of these precursor lesions is important. Diagnosing STIC can have prognostic consequences and is an absolute requirement for safely offering alternative risk reducing strategies, such as risk reducing salpingectomy with delayed oophorectomy. However, diagnosing STIC is a challenging task, possessing only moderate reproducibility. In this review and meta-analysis, we look at how pathologists come to a diagnosis of STIC. We performed a literature search identifying 39 studies on risk reducing salpingo-oophorectomy in women with a known BRCA1/2 PV, collectively reporting on 6833 patients. We found a pooled estimated proportion of STIC of 2.8% (95% CI, 2.0-3.7). We focused on reported grossing protocols, morphological criteria, level of pathologist training, and the use of immunohistochemistry. The most commonly mentioned morphological characteristics of STIC are (1) loss of cell polarity, (2) nuclear pleomorphism, (3) high nuclear to cytoplasmic ratio, (4) mitotic activity, (5) pseudostratification, and (6) prominent nucleoli. The difference in reported incidence of STIC between studies who totally embedded all specimens and those who did not was 3.2% (95% CI, 2.3-4.2) versus 1.7% (95% CI, 0.0-6.2) (p 0.24). We provide an overview of diagnostic features and present a framework for arriving at an adequate diagnosis, consisting of the use of the SEE-FIM grossing protocol, evaluation by a subspecialized gynecopathologist, rational use of immunohistochemical staining, and obtaining a second opinion from a colleague.

Identifiants

pubmed: 34850262
doi: 10.1007/s00428-021-03244-w
pii: 10.1007/s00428-021-03244-w
pmc: PMC9023413
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-737

Informations de copyright

© 2021. The Author(s).

Références

Am J Surg Pathol. 2006 Oct;30(10):1222-30
pubmed: 17001151
Int J Gynecol Cancer. 2019 May 2;:
pubmed: 31048403
Gynecol Oncol. 2016 Nov;143(2):231-235
pubmed: 27623252
JAMA. 2017 Dec 12;318(22):2199-2210
pubmed: 29234806
Int J Gynecol Cancer. 2012 Jul;22(6):974-8
pubmed: 22740003
Int J Gynecol Pathol. 2004 Jan;23(1):41-4
pubmed: 14668549
Am J Surg Pathol. 2011 Dec;35(12):1766-75
pubmed: 21989347
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Int J Gynecol Pathol. 2011 Sep;30(5):417-24
pubmed: 21804388
Am J Surg Pathol. 2010 Jun;34(6):829-36
pubmed: 20431479
Int J Gynecol Cancer. 2017 May;27(4):703-707
pubmed: 28399030
Int J Gynecol Pathol. 2010 Jul;29(4):310-4
pubmed: 20567141
JAMA. 2006 Jul 12;296(2):185-92
pubmed: 16835424
Obstet Gynecol. 2019 Sep;134(3):520-526
pubmed: 31403600
Gynecol Oncol. 2017 Aug;146(2):373-379
pubmed: 28577884
Mod Pathol. 2017 May;30(5):710-721
pubmed: 28106106
Gynecol Oncol Rep. 2019 Feb 01;28:18-22
pubmed: 30775416
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
Gynecol Oncol. 2012 Oct;127(1):88-93
pubmed: 22710074
Am J Obstet Gynecol. 2006 Jun;194(6):1702-9
pubmed: 16731090
J Clin Oncol. 2014 Oct 10;32(29):3275-83
pubmed: 25199754
Virchows Arch. 2016 Jun;468(6):707-13
pubmed: 27003156
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Int J Gynecol Cancer. 2013 Nov;23(9):1603-11
pubmed: 24172097
Clin Transl Oncol. 2018 Oct;20(10):1337-1344
pubmed: 29623583
Int J Gynecol Pathol. 2012 May;31(3):243-53
pubmed: 22498942
Am J Surg Pathol. 2006 Feb;30(2):230-6
pubmed: 16434898
J Pathol Transl Med. 2018 Jan;52(1):21-27
pubmed: 27539290
Br J Surg. 2020 Apr;107(5):519-524
pubmed: 32129898
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
Clin Med Res. 2007 Mar;5(1):35-44
pubmed: 17456833
J Pathol Clin Res. 2016 Jul 13;2(4):247-258
pubmed: 27840695
Int J Gynecol Cancer. 2016 Oct;26(8):1415-20
pubmed: 27488216
J Clin Pathol. 2021 May;74(5):271-272
pubmed: 33208404
Histopathology. 2018 Jul;73(1):109-123
pubmed: 29484698
Int J Gynecol Cancer. 2009 Jul;19(5):826-9
pubmed: 19574767
J Pathol. 2012 Feb;226(3):421-6
pubmed: 21990067
Gynecol Oncol. 2019 Feb;152(2):426-433
pubmed: 30503267
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68
pubmed: 29718305
BJOG. 2017 May;124(6):872-878
pubmed: 28218502
Anticancer Res. 2017 Sep;37(9):5241-5248
pubmed: 28870960
J Natl Cancer Inst. 2013 Dec 18;105(24):1897-906
pubmed: 24203987
Climacteric. 2017 Jun;20(3):212-221
pubmed: 28509627
BMC Cancer. 2015 Aug 19;15:593
pubmed: 26286255
Int J Gynecol Pathol. 2004 Jan;23(1):35-40
pubmed: 14668548
Lancet Oncol. 2020 Feb;21(2):233-241
pubmed: 31926805
Fam Cancer. 2017 Oct;16(4):461-469
pubmed: 28285341
Radiol Oncol. 2020 May 28;54(2):180-186
pubmed: 32463390
Eur J Cancer. 2013 Jan;49(1):132-41
pubmed: 22921157
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S9-S24
pubmed: 30550481
J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):837-842
pubmed: 28479170
Gynecol Oncol. 2019 May;153(2):326-334
pubmed: 30894273
Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471
pubmed: 29691126
Eur J Surg Oncol. 2020 Jan;46(1):139-147
pubmed: 31521389
Am J Surg Pathol. 2009 Dec;33(12):1878-85
pubmed: 19898224
Ir J Med Sci. 2018 Aug;187(3):789-794
pubmed: 29299762
J Gynecol Oncol. 2017 Jan;28(1):e3
pubmed: 27670257
Gynecol Oncol. 2013 May;129(2):364-71
pubmed: 23391663
BJOG. 2011 Jun;118(7):814-24
pubmed: 21392246
Gynecol Oncol. 2014 Feb;132(2):280-6
pubmed: 24333842
Eur J Obstet Gynecol Reprod Biol. 2020 Apr;247:26-31
pubmed: 32059136
Gynecol Oncol. 2020 May;157(2):514-520
pubmed: 32199636
Int J Gynecol Pathol. 2020 May;39(3):261-269
pubmed: 31033800
Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:110-112
pubmed: 29704813
J Ovarian Res. 2019 May 25;12(1):50
pubmed: 31128592
Cancer Prev Res (Phila). 2018 Nov;11(11):697-706
pubmed: 30232083
Histopathology. 2008 Aug;53(2):127-38
pubmed: 18298580
Int J Gynecol Cancer. 2011 Jul;21(5):846-51
pubmed: 21670699
Nature. 2000 Nov 16;408(6810):307-10
pubmed: 11099028
JNCI Cancer Spectr. 2018 Dec 14;2(4):pky061
pubmed: 31360879
Mod Pathol. 2009 Sep;22(9):1133-8
pubmed: 19543244
Gynecol Oncol. 2014 Sep;134(3):492-7
pubmed: 25026639

Auteurs

Joep M A Bogaerts (JMA)

Department of Pathology, Radboud University Medical Center, Postbus 9101, 6500 HB, Nijmegen, The Netherlands. joep.bogaerts@radboudumc.nl.

Miranda P Steenbeek (MP)

Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.

Majke H D van Bommel (MHD)

Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.

Johan Bulten (J)

Department of Pathology, Radboud University Medical Center, Postbus 9101, 6500 HB, Nijmegen, The Netherlands.

Jeroen A W M van der Laak (JAWM)

Diagnostic Image Analysis Group, Radboud University Medical Center, Nijmegen, The Netherlands.

Joanne A de Hullu (JA)

Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.

Michiel Simons (M)

Department of Pathology, Radboud University Medical Center, Postbus 9101, 6500 HB, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH